Skip to main content

Table 2 Summary of eligible studies on kidney function, n = 2 studies

From: Late effects of high-dose methotrexate treatment in childhood cancer survivors—a systematic review

First author
Year
Country
Final cohort (male:female), diagnosis and cohort description Age at diagnosis [years] Follow-up [years] Method Effect of HD-MTX
Grönroos et al. 2008
Finland
28 (12:16); ALL, lymphoma Median 7.7 (range 1.5–15.4) Median 6.0 (range 1.0–10.0) iGFR with 51CR-EDTA or 99mTc-DTPA, urinalysis continuous variables 8 g/m2/dose vs. 5 g/m2/dose
▪Albuminuria: no sign. association with its occurrence (OR 1.50, 95%CI 0.29–0.78)
▪Proteinuria: no sign. association with its occurrence (OR 4.67, 95%CI 0.42–52.12)
Study group:
▪Group I: HD-MTX (n = 28)
5 g/m2/dose: n = 16
8 g/m2/dose: n = 12
Follow-up: since end of treatment Definition:
▪iGFR: reduced if iGFR
▪ < 115 ml/min/1.73m2
▪Urinary albuminuria: abnormal if albumin/creatinine ratio > 2.5 mg/mmol
8 g/m2/dose vs. 5 g/m2/dose
▪iGFR: no sign. association with reduced iGFR
Higher cumulative dose:
▪iGFR: no sign. association with reduced iGFR
▪Albuminuria: no sign. association with its occurrence
▪Proteinuria: no sign. association with its occurrence
Mulder et al. 2013
The Netherlands
1122 (599:523); different tumors Median 7.6 (range 0.0–17.8) Median 15.3 (5.0–36.1) GFR (CKD-EPI formula for adults) continuous variables Higher cumulative dose:
▪GFR: no sign. association with reduced GFR
Study group:
▪Group I: HD-MTX (n = 253)
Follow-up: since diagnosis Definition:
▪GFR reduced if GFR < 90 ml/min/ 1.73m2
Exposure:
▪GFR over time: no sign. effect of HD-MTX on deterioration of GFR over time
  1. ALL acute lymphoblastic leukemia, CI confidence interval, CKD-EPI Chronic Kidney Disease Epidemiology Collaboration, GFR glomerular filtration rate, HD-MTX high-dose methotrexate, iGFR isotope glomerular filtration rate, n number, OR odds ratio, sign. significant(ly). Numbers taken from the original article even though OR is not within the 95%CI